PE20091713A1 - INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS - Google Patents

INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS

Info

Publication number
PE20091713A1
PE20091713A1 PE2008001959A PE2008001959A PE20091713A1 PE 20091713 A1 PE20091713 A1 PE 20091713A1 PE 2008001959 A PE2008001959 A PE 2008001959A PE 2008001959 A PE2008001959 A PE 2008001959A PE 20091713 A1 PE20091713 A1 PE 20091713A1
Authority
PE
Peru
Prior art keywords
seq
macrophagus
ron
receptor
inhibition
Prior art date
Application number
PE2008001959A
Other languages
Spanish (es)
Inventor
Daniel Pereira
Jennifer O'toole
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PE20091713A1 publication Critical patent/PE20091713A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE ESPECIFICAMENTE A UNA PROTEINA RON (PROTEINA ESTIMULANTE DEL MACROFAGO) QUE COMPRENDE UNA CDR SELECCIONADA DE SEQ ID NO: 17; SEQ ID NO 19; SEQ ID NO 21; SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37 Y SEQ ID NO 39. TAMBIEN ESTA REFERIDA A UN VECTOR RECOMBINANTE, UNA CELULA HUESPED Y A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DEL CANCERREFERRING TO AN ANTIBODY OR ANTIBODY FRAGMENT THAT SPECIFICALLY Binds TO A RON PROTEIN (MACROPHAGUS STIMULATING PROTEIN) THAT INCLUDES A SELECTED CDR OF SEQ ID NO: 17; SEQ ID NO 19; SEQ ID NO 21; SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37 AND SEQ ID NO 39. IT IS ALSO REFERRED TO A RECOMBINANT VECTOR, A HOST CELL AND A PHARMACEUTICAL COMPOSITION. SUCH ANTIBODIES ARE USEFUL IN THE TREATMENT OF CANCER

PE2008001959A 2007-11-21 2008-11-24 INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS PE20091713A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
PE20091713A1 true PE20091713A1 (en) 2009-11-13

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001959A PE20091713A1 (en) 2007-11-21 2008-11-24 INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS

Country Status (20)

Country Link
US (2) US7947811B2 (en)
EP (1) EP2222703A2 (en)
JP (1) JP5324593B2 (en)
KR (1) KR101227338B1 (en)
CN (1) CN101868478B (en)
AR (1) AR069393A1 (en)
AU (1) AU2008330089B2 (en)
BR (1) BRPI0820218A2 (en)
CA (1) CA2706583A1 (en)
CL (1) CL2008003449A1 (en)
EA (1) EA018717B1 (en)
IL (1) IL204743A (en)
MX (1) MX2010005651A (en)
NZ (1) NZ584271A (en)
PA (1) PA8804901A1 (en)
PE (1) PE20091713A1 (en)
TW (1) TWI417106B (en)
UA (1) UA99633C2 (en)
UY (1) UY31478A1 (en)
WO (1) WO2009070294A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336832T3 (en) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. COMPOSITIONS AND PROCEDURES TO TREAT DISEASES WITH FGFR FUSION PROTEINS.
CA2712697A1 (en) * 2008-01-22 2009-07-30 Biogen Idec Ma Inc. Ron antibodies and uses thereof
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (en) 2008-02-06 2010-03-31 Osi Pharm Inc FURO (3,2-C) PIRIDINE AND HAVING (3,2-C) PIRIDINES
TWI480050B (en) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd Anti-mst1r antibodies and uses thereof
JP5856073B2 (en) * 2009-12-29 2016-02-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー RON binding construct and method of use thereof
CA2804399A1 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2699256B1 (en) * 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
US20130136740A1 (en) 2011-11-14 2013-05-30 Thomas Harding Methods of treating cancer
BR112015012649A2 (en) * 2012-11-30 2017-07-11 Genentech Inc ron agonist, pharmaceutical composition, methods, msp fusion protein, isolated nucleic acid molecules, vectors, host cells and isolated antibodies.
JP2016512489A (en) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー Anti-MCSP antibody
JP2016510755A (en) 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド Anti-C-MET Tandem Fc Bispecific Antibody
EP3176268B1 (en) * 2014-07-29 2019-07-17 Wellmarker Bio Co., Ltd. Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
WO2016036172A1 (en) * 2014-09-03 2016-03-10 씨제이헬스케어 주식회사 Biomarker for predicting sensitivity to protein kinase inhibitor and use thereof
WO2018038684A1 (en) * 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CA3192706A1 (en) * 2020-09-15 2022-03-24 Gregory SEMPOWSKI Coronavirus antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0536350B1 (en) 1991-02-22 2002-08-07 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
ATE408012T1 (en) 1991-12-02 2008-09-15 Medical Res Council PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
PT817775E (en) 1995-03-30 2002-01-30 Pfizer QUINAZOLINE DERIVATIVES
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP2004511430A (en) 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
CA2418083A1 (en) 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
SE518548C2 (en) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorbent articles with improved discretion
AU2002258798A1 (en) 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
JP2005500034A (en) 2001-06-20 2005-01-06 プロション バイオテク リミテッド Antibody that blocks activation of receptor protein tyrosine kinase, screening method thereof, and use thereof
US7498414B2 (en) 2002-03-04 2009-03-03 Imclone Systems Incorporated Human antibodies specific to KDR and uses thereof
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
JP2007535895A (en) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド Fully human antibody against human insulin-like growth factor-1 receptor
JP2008508858A (en) * 2004-05-13 2008-03-27 イムクローン システムズ インコーポレイティド Inhibition of macrophage-stimulated protein receptor (RON)

Also Published As

Publication number Publication date
US20090136510A1 (en) 2009-05-28
PA8804901A1 (en) 2009-06-23
WO2009070294A3 (en) 2009-08-20
KR101227338B1 (en) 2013-01-28
IL204743A (en) 2013-10-31
BRPI0820218A2 (en) 2015-06-23
JP2011504176A (en) 2011-02-03
WO2009070294A2 (en) 2009-06-04
US7947811B2 (en) 2011-05-24
TWI417106B (en) 2013-12-01
US20110135631A1 (en) 2011-06-09
US8133489B2 (en) 2012-03-13
IL204743A0 (en) 2010-11-30
AR069393A1 (en) 2010-01-20
JP5324593B2 (en) 2013-10-23
AU2008330089A1 (en) 2009-06-04
EA201070636A1 (en) 2010-10-29
CN101868478A (en) 2010-10-20
MX2010005651A (en) 2010-06-11
UY31478A1 (en) 2009-07-17
AU2008330089B2 (en) 2013-09-05
EA018717B1 (en) 2013-10-30
CL2008003449A1 (en) 2010-02-19
CN101868478B (en) 2013-11-13
NZ584271A (en) 2012-05-25
UA99633C2 (en) 2012-09-10
KR20100074293A (en) 2010-07-01
TW200936161A (en) 2009-09-01
CA2706583A1 (en) 2009-06-04
EP2222703A2 (en) 2010-09-01

Similar Documents

Publication Publication Date Title
PE20091713A1 (en) INHIBITION OF THE RECEPTOR FOR MACROPHAGUS STIMULATING PROTEIN (RON), COMPOSITIONS AND METHODS
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PE20120431A1 (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
AR060017A1 (en) COMPOSITIONS AND METHODS OF USE FOR DICKKOPF -1 ANTIBODIES
PE20110225A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5
CY1115572T1 (en) CXCR4 ANTIBODIES AND USE OF THESE FOR CANCER TREATMENT
PE20091196A1 (en) ANTIBODIES AGAINST COMPLETELY HUMAN VEGF, COMPOSITIONS AND METHODS
PE20091163A1 (en) ANTIBODIES FOR GDF8
DE602007013282D1 (en) MONOCLONAL ANTIBODIES TO THE HUMAN TYPE II ANTI-MÜLLERIAN HORMONE RECEPTOR (AMHR-II)
EA201100546A1 (en) POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
MX2013011363A (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2.
PE20121129A1 (en) HUMAN ANTIBODIES OF HIGH AFFINITY FOR HUMAN ANGIOPOYETIN-2
PE20130207A1 (en) ANTIBODIES ANTAGONISTS TO LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS
EA201992526A1 (en) STABILITIES OF ANTI-CTLA4 ANTIBODIES, SEPARATELY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF APPLICATION
MX2009002711A (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma.
EA201170590A1 (en) FIBROBLAST-3 GROWTH FACTOR RECEPTOR INHIBITORS (FGFR-3) AND TREATMENT METHODS
CL2012000914A1 (en) Monoclonal antibodies that specifically bind to the c-terminal region of progastrin. use for the preparation of a useful medicine in the treatment of colorectal cancer.
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
PE20091193A1 (en) HUMAN ANTIGEN BINDING PROTEINS FROM GM-CSF
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody
PE20180502A1 (en) ANTI-CGRP COMPOSITIONS AND USE OF THEM
EA200970210A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
BRPI0613382A8 (en) isolated antibodies, monoclonal antibody, hybridoma cell, identification method, cell growth inhibition method, therapeutic treatment method, protein presence determination method, tumor presence diagnosis methods
AR074360A1 (en) MONOCLONAL ANTIBODY OR FRAGMENT OF UNION TO ANTIGEN OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
PE20110306A1 (en) HUMAN ANTIBODIES THAT JOIN LYMPHOCYTARY ACTIVATION GEN 3 (LAG-3)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed